Drug Database
DO

doxazosin (Cardura XL / doxazosin, GITS / Cardura CR)

✓ Approved

Ipsen Pharma · Small Molecule · Small Molecule

What is doxazosin?

doxazosin is a small molecule developed by Ipsen Pharma. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesCardura XL, doxazosin, GITS, Cardura CR
CompanyIpsen Pharma
Drug ClassSmall Molecule
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Ipsen Pharma

Therapeutic Indications

doxazosin is developed for 2 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Vascular disordersHypertension✓ Approved
Reproductive system and breast disordersBenign prostatic hyperplasia✓ Approved

Related Research Articles

PubMedDrugs in context2026-09-18

Cardiovascular effects of doxazosin in the treatment of prostatic hyperplasia.

Fan Qianhui Q, Fan Libin L, Kuang Shihang S, Li Huafu H

Doxazosin, a selective α1-receptor antagonist, is widely used to treat lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). However, its cardiovascular effects remain clinically relevant, particularly in older patients. This systematic review and meta-analysis evaluated blood pressure, heart rate, headache and vertigo during doxazosin treatment. PubMed/MEDLINE, the Cochrane Library, CNKI, Wanfang Data, Google Scholar and ScienceDirect were searched using Chinese and English terms related to doxazosin, BPH, prostate and cardiovascular outcomes. Sixteen evidence reports were included: 12 primary studies, 2 pooled analyses and 2 secondary review sources that supplied aggregate trial data. The pooled analyses showed no statistically significant difference in systolic blood pressure (MD 1.44, 95% CI -4.17 to 7.06; p=0.61), diastolic blood pressure (MD -0.33, 95% CI -3.68 to 3.03; p=0.85), headache (OR 0.99, 95% CI 0.73-1.34; p=0.95) or heart rate (MD 0.98, 95% CI -0.89 to 2.84; p=0.30). Vertigo was more frequent with doxazosin than with control treatment (OR 1.93, 95% CI 1.50-2.49; p<0.00001). Risk-of-bias assessment identified 2 reports at low risk, 10 with some concerns, 1 at high risk, 1 observational study of moderate quality, and 2 secondary reviews for which Cochrane Risk of Bias 2 and the Newcastle-Ottawa Scale were not applicable. Doxazosin was not associated with statistically significant average changes in blood pressure or heart rate, but the increased occurrence of vertigo warrants counselling and monitoring, particularly in older patients at risk of falls.

PMID 42756977
Read full article →
PubMedIJU case reports2026-09-13

Preoperative Diagnosis of Bladder Paraganglioma Followed by Robot-Assisted Partial Cystectomy: A Case Report.

Takagi Kimiaki K, Maekawa Yuka Y, Yamada Toyohiro T, Ozawa Hiroyuki H et al.

Bladder paraganglioma is a rare neuroendocrine tumor for which accurate preoperative diagnosis is important because tumor manipulation may provoke catecholamine-related hemodynamic instability. A 58-year-old man presented with hematuria. Cystoscopy revealed a submucosal bladder tumor. Contrast-enhanced computed tomography and magnetic resonance imaging demonstrated a 2-cm bladder wall mass with characteristic findings suggestive of paraganglioma. Although catecholamine levels were within normal limits and no adrenergic symptoms were present, metaiodobenzylguanidine scintigraphy showed uptake in the lesion, supporting the diagnosis. To avoid the potential risk associated with TUR, preoperative alpha-adrenergic blockade with doxazosin was administered, followed by robot-assisted partial cystectomy. No significant intraoperative hemodynamic instability occurred. Histopathological examination confirmed paraganglioma. Recognition of characteristic imaging findings may facilitate preoperative diagnosis and safe surgical management of bladder paraganglioma. Robot-assisted partial cystectomy was a feasible minimally invasive treatment option.

PMID 42729233
Read full article →
PubMedBioImpacts : BI2026-08-29

Correction to: Sustained release microneedle patch for pronounced systemic delivery of doxazosin mesylate.

Anwar Imran I, Zafar Nadiah N, Mahmood Asif A, Zulcaif

[This corrects the article DOI: 10.15171/bi.30257.].

PMID 42666976
Read full article →
PubMedEuropean heart journal. Case reports2026-08-14

A case of cardiac paraganglioma in a patient with SDHC-related hereditary paraganglioma pheochromocytoma syndrome.

Bhalla Jaideep Singh JS, Saraswati Ushasi U, Bansal Agam A, Abou Hassan Ossama O et al.

Cardiac paragangliomas are rare neoplasms, comprising only 1%-3% of primary cardiac tumours, and often pose a diagnostic challenge. A 56-year-old male presented with persistent chest pressure, palpitations and diaphoresis. Cardiac catheterization and further imaging revealed the presence of a fluorodeoxyglucose-avid enhancing epicardial mass accompanied by elevated serum catecholamines. Treatment with doxazosin followed by surgical resection was performed, confirming the diagnosis of cardiac paraganglioma on pathology. Whilst rare, cardiac paragangliomas can be hormonally active and symptomatic, necessitating operative management. Accurate differentiation from similar masses on imaging aids in guiding preoperative hormonal evaluations and medical management, as well as in conducting genetic testing to identify causative mutations and assess heritability.

PMID 42598202
Read full article →
PubMedJournal of clinical medicine2026-08-13

Breaking the Cycle of Polypharmacy: A Case Report of Renal Denervation in Resistant Hypertension.

Szwarkowska Maria M, Petela Tymoteusz T, Zeliaś Aleksander A, Skowerski Tomasz T et al.

Background: Resistant hypertension poses a significant therapeutic challenge, often leading to severe polypharmacy. Renal denervation (RDN) has re-emerged as a valuable adjunctive intervention for blood pressure control. Case Presentation: We report the case of a 64-year-old man (body mass index [BMI] 34 kg/m2) with long-standing resistant hypertension (RH), after previous percutaneous coronary intervention (PCI) to the left anterior descending artery, heart failure with preserved ejection fraction (HFpEF), and prior nephron-sparing surgery for clear cell renal carcinoma. Despite treatment with an extensive antihypertensive regimen encompassing nine pharmacological classes including diuretic therapy (angiotensin-converting enzyme inhibitor; calcium channel blocker, thiazide diuretic, β-blocker, α1-blocker, central α2-agonist, mineralocorticoid receptor antagonist, loop diuretic, long-acting nitrates), blood pressure remained severely uncontrolled on both home and office measurements. Persistent hypertension was accompanied by exertional dyspnoea and episodes of exertional chest discomfort. Following comprehensive evaluation and exclusion of secondary causes of hypertension, the patient underwent catheter-based renal denervation using the SymplicitySpyral™ (Medtronic) multi-electrode radiofrequency system. The procedure was associated with substantial and sustained improvement in blood pressure control, with mean 24 h ambulatory blood pressure measurements decreasing to 130/80 mmHg at six-month follow-up. Importantly, successful blood pressure reduction enabled major simplification of pharmacotherapy, including complete discontinuation of clonidine, loop diuretic therapy, and long-acting nitrates, together with marked dose reduction in doxazosin. Conclusions: This case illustrates the potential clinical utility of renal denervation in carefully selected patients with true resistant hypertension and pronounced sympathetic overactivity. Beyond achieving satisfactory blood pressure control, RDN may facilitate meaningful reduction in medication burden, potentially improving treatment adherence, quality of life, and long-term cardiovascular risk. Written informed consent was obtained from the patient for both the procedure and the publication of this case report.

PMID 42589942
Read full article →
PubMedJournal of clinical hypertension (Greenwich, Conn.)2026-07-25

Serum Uric Acid Changes in Relation to Nighttime Blood Pressure Dipping Status in Patients on Antihypertensive Therapy.

Zhang Di D, Huang Qi-Fang QF, Li Yan Y, Wang Ji-Guang JG

We performed a post hoc exploratory secondary analysis to investigate whether baseline circadian blood pressure (BP) pattern was associated with changes in serum uric acid (SUA) during 8-week antihypertensive therapy. Of the 494 hypertensive patients who received amlodipine (5-10 mg) or nifedipine GITS (30-60 mg) for 8 weeks, 369 patients with available laboratory data and valid follow-up ambulatory BP monitoring data were included in the present analysis, including 221 dippers (nocturnal systolic BP decline ≥ 10%) and 148 non-dippers (nocturnal systolic BP decline < 10%). Analysis of covariance was used to estimate least square mean changes in SUA according to baseline dipping pattern. After 8-week antihypertensive treatment, SUA decreased significantly in dippers (-12.4 ± 3.4 µmol/L, p = 0.0004) but not in non-dippers (-3.3 ± 4.2 µmol/L, p = 0.44). In the repeated-measures analysis, SUA levels decreased significantly over time (p = 0.002), whereas no significant time-by-dipping interaction was observed (p = 0.23). Baseline BP dipping pattern may be modestly associated with short-term SUA changes during antihypertensive therapy. However, the absence of a significant time-by-dipping interaction suggests that these findings should be interpreted cautiously and require further confirmation.

PMID 42501048
Read full article →

+2276 more articles available with a free account

Sign up free to view all articles →

Ask about doxazosin